A Phase II Study of Intravenous Methotrexate and Cranial Irradiation in the Treatment of Primary Central Nervous System Lymphoma (PCNSL)

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

Related Post

28 March, 2025

TROG Awards Recognise Research Excellence

Latest news: 28 March 2025. TROG Members who have

27 March, 2025

TROG 2025 ASM advances inclusivity and innovation

Latest news: 27 March 2025 With a theme of